Ameliorating the effect and mechanism of chitosan oligosaccharide on nonalcoholic fatty liver disease in mice-Reference-Cited by-同舟云学术

Ameliorating the effect and mechanism of chitosan oligosaccharide on nonalcoholic fatty liver disease in mice

Published:2023 Issue:23 Volume:14 Page:10459-10474
ISSN:2042-6496
Container-title:Food & Function
language:en
Short-container-title:Food Funct.

Author:

Zhang Jiahua¹²,Feng Jiayao¹²,Bai Yan³,Che Qishi⁴,Cao Hua⁵^ORCID,Guo Jiao²,Su Zhengquan¹^ORCID

Affiliation:

1. Guangdong Engineering Research Center of Natural Products and New Drugs, Guangdong Provincial University Engineering Technology Research Center of Natural Products and Drugs, Guangdong Pharmaceutical University, Guangzhou (510006), China

2. Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, Guangdong TCM Key Laboratory for Metabolic Diseases, Guangdong Pharmaceutical University, Guangzhou (510006), China

3. School of Public Health, Guangdong Pharmaceutical University, Guangzhou (510310), China

4. Guangzhou Rainhome Pharm & Tech Co., Ltd, Science City, Guangzhou (510663), China

5. School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Zhongshan (528458), China

Abstract

Previous studies have found that chitosan oligosaccharide (COST) can alleviate the clinical symptoms in non-alcoholic fatty liver disease (NAFLD) patients.

Funder

Guangzhou Municipal Science and Technology Project

Natural Science Foundation of Guangdong Province for Distinguished Young Scholars

Publisher

Royal Society of Chemistry (RSC)

Subject

General Medicine,Food Science

Link

http://pubs.rsc.org/en/content/articlepdf/2023/FO/D3FO03745B

Reference45 articles.

1. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease

2. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

3. The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis

4. Antioxidant Peptides from Monkfish Swim Bladders: Ameliorating NAFLD In Vitro by Suppressing Lipid Accumulation and Oxidative Stress via Regulating AMPK/Nrf2 Pathway

5. Linking Pathogenic Mechanisms of Alcoholic Liver Disease With Clinical Phenotypes

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The preparation, modification and hepatoprotective activity of chitooligosaccharides: A review;International Journal of Biological Macromolecules;2024-10

2. Chitosan-Stabilized Selenium Nanoparticles Alleviate High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease (NAFLD) by Modulating the Gut Barrier Function and Microbiota;Journal of Functional Biomaterials;2024-08-22

3. The gut-liver axis in fatty liver disease: role played by natural products;Frontiers in Pharmacology;2024-04-15